JP7618599B2 - 前立腺特異的膜抗原を標的とする放射性標識化合物 - Google Patents

前立腺特異的膜抗原を標的とする放射性標識化合物 Download PDF

Info

Publication number
JP7618599B2
JP7618599B2 JP2021576163A JP2021576163A JP7618599B2 JP 7618599 B2 JP7618599 B2 JP 7618599B2 JP 2021576163 A JP2021576163 A JP 2021576163A JP 2021576163 A JP2021576163 A JP 2021576163A JP 7618599 B2 JP7618599 B2 JP 7618599B2
Authority
JP
Japan
Prior art keywords
aromatic
group
xaa
groups
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021576163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537773A5 (https=
JP2022537773A (ja
Inventor
リン，クオ－シュヤン
ベナール，フランソワ
クオ，ショウ－ティン
ジャン，ジョンシン
ペラン，ダヴィド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Provincial Health Services Authority
Original Assignee
Provincial Health Services Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provincial Health Services Authority filed Critical Provincial Health Services Authority
Publication of JP2022537773A publication Critical patent/JP2022537773A/ja
Publication of JP2022537773A5 publication Critical patent/JP2022537773A5/ja
Priority to JP2025002658A priority Critical patent/JP2025069156A/ja
Application granted granted Critical
Publication of JP7618599B2 publication Critical patent/JP7618599B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021576163A 2019-06-21 2020-06-19 前立腺特異的膜抗原を標的とする放射性標識化合物 Active JP7618599B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025002658A JP2025069156A (ja) 2019-06-21 2025-01-08 前立腺特異的膜抗原を標的とする放射性標識化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962865088P 2019-06-21 2019-06-21
US62/865,088 2019-06-21
US202063006643P 2020-04-07 2020-04-07
US63/006,643 2020-04-07
PCT/CA2020/050864 WO2020252598A1 (en) 2019-06-21 2020-06-19 Radiolabeled compounds targeting the prostate-specific membrane antigen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025002658A Division JP2025069156A (ja) 2019-06-21 2025-01-08 前立腺特異的膜抗原を標的とする放射性標識化合物

Publications (3)

Publication Number Publication Date
JP2022537773A JP2022537773A (ja) 2022-08-29
JP2022537773A5 JP2022537773A5 (https=) 2023-06-26
JP7618599B2 true JP7618599B2 (ja) 2025-01-21

Family

ID=74036930

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576163A Active JP7618599B2 (ja) 2019-06-21 2020-06-19 前立腺特異的膜抗原を標的とする放射性標識化合物
JP2025002658A Pending JP2025069156A (ja) 2019-06-21 2025-01-08 前立腺特異的膜抗原を標的とする放射性標識化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025002658A Pending JP2025069156A (ja) 2019-06-21 2025-01-08 前立腺特異的膜抗原を標的とする放射性標識化合物

Country Status (10)

Country Link
US (2) US11504441B2 (https=)
EP (1) EP3986872A4 (https=)
JP (2) JP7618599B2 (https=)
KR (1) KR20220024595A (https=)
CN (2) CN114401947B (https=)
AU (1) AU2020296488A1 (https=)
BR (1) BR112021025810A2 (https=)
CA (1) CA3144094A1 (https=)
IL (1) IL288960B1 (https=)
WO (1) WO2020252598A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020257786B2 (en) 2019-04-17 2025-10-23 Provincial Health Services Authority Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
GB202005282D0 (en) 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
EP4263509A4 (en) * 2020-12-16 2024-12-04 The University of British Columbia RADIOACTIVELY LABELLED COMPOUNDS FOR TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
JP2024512283A (ja) * 2021-02-26 2024-03-19 テリックス ファーマシューティカルズ （イノベーションズ） ピーティーワイ リミテッド グルタメート－尿素－リジン由来（ｇｕｌ由来）前立腺特異的膜抗原（ｐｓｍａ）標的化コンジュゲートの固相合成並びに治療剤及び／又は診断剤のための前駆体としてのそれらの使用
CN115806529A (zh) * 2021-09-15 2023-03-17 威智医药有限公司 Psma结合剂及其用途
WO2023083209A1 (zh) * 2021-11-10 2023-05-19 苏州瑞核医药科技有限公司 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用
CA3244865A1 (en) * 2022-03-04 2023-09-07 Provincial Health Services Authority RADIOLABELLED COMPOUNDS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN
CN115010629B (zh) * 2022-06-07 2024-02-23 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用
WO2024016071A1 (en) * 2022-07-18 2024-01-25 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
CN118344391A (zh) * 2023-01-13 2024-07-16 浙江普利药业有限公司 一种新的用于硼中子捕获疗法的含硼化合物
WO2024169037A1 (zh) * 2023-02-16 2024-08-22 无锡诺宇医药科技有限公司 Psma靶向放射性药物及其合成和应用
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
CN116730983B (zh) * 2023-08-10 2023-11-03 山东大学 一种靶向前列腺特异性抗原的化合物及其制备方法与应用
CN120202191A (zh) 2023-09-12 2025-06-24 上海先通生物科技有限公司 前列腺特异性膜抗原的抑制剂和其用途
CN121773094A (zh) 2023-09-12 2026-03-31 上海先通生物科技有限公司 前列腺特异性膜抗原的抑制剂和其用途
CN117045828A (zh) * 2023-10-12 2023-11-14 北京先通国际医药科技股份有限公司 212Pb标记的放射性化合物在制备治疗前列腺癌药物中的用途
CN119101006B (zh) * 2024-09-05 2025-11-07 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性标记物及制法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075583A1 (en) 2017-10-22 2019-04-25 British Columbia Cancer Agency Branch NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US7563433B2 (en) 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
JP2007524677A (ja) 2004-02-13 2007-08-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 放射性標識化合物及び組成物、それらの前駆体及びそれらの製造方法
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
EP2097111B1 (en) 2006-11-08 2015-07-15 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
ES2700234T3 (es) 2007-06-26 2019-02-14 Univ Johns Hopkins Inhibidores marcados del antígeno de membrana específico de la próstata (PSMA), evaluación biológica y uso como agentes para la obtención de imágenes
WO2009012596A1 (en) 2007-07-24 2009-01-29 The University Of British Columbia Substituted aryl-fluoroborates as imaging agents
PT2318366T (pt) 2008-08-01 2017-08-02 Univ Johns Hopkins Agentes de ligação a psma e suas utilizações
WO2012094334A1 (en) 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
AU2012223364A1 (en) 2011-03-01 2013-09-19 Ge Healthcare Limited Radiolabelled Octreotate analogues as PET tracers
WO2013028791A1 (en) 2011-08-22 2013-02-28 British Columbia Cancer Agency Branch 18f compounds for cancer imaging and methods for their use
WO2013028664A1 (en) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
US20140147381A1 (en) 2012-11-29 2014-05-29 Gregory David Espenan 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment
WO2014134716A1 (en) 2013-03-08 2014-09-12 The University Of British Columbia Substituted organofluoroborates as imaging agents
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
CA2972058C (en) 2014-01-03 2022-05-24 British Columbia Cancer Agency Branch Compositions and methods for imaging cancer
WO2015135082A1 (en) 2014-03-13 2015-09-17 British Columbia Cancer Agency Branch Bradykinin receptor b1 targeting probes
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
EP3400229B1 (en) 2016-01-10 2024-03-06 Provincial Health Services Authority 18/19f-labelled compounds which target the prostate specific membrane antigen
MX2019005742A (es) 2016-11-23 2019-09-13 Cancer Targeted Tech Llc Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
CN106967152B (zh) 2017-03-28 2019-11-26 江苏省原子医学研究所 一种氟-18标记的化合物及其制备方法与应用
CA3060143A1 (en) 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
JP7144451B2 (ja) * 2017-06-06 2022-09-29 クラリティー・ファーマシューティカルズ・リミテッド 放射性医薬品、放射線造影剤及びそれらの使用
BR112020011727A2 (pt) 2017-12-11 2020-11-17 Technische Universität München ligantes de psma para imageamento e endorradioterapia
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
EP3856261A1 (en) 2018-09-28 2021-08-04 Universität Heidelberg Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
US12427209B2 (en) 2018-12-18 2025-09-30 Provincial Health Services Authority Dual mode 18F-labelled theranostic compounds and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019075583A1 (en) 2017-10-22 2019-04-25 British Columbia Cancer Agency Branch NOVEL RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kuo, H.-T. et al.，"A 177Lu-labeled albumin-binder-conjugated PSMA-617 derivative with greatly enhanced radiation dose delivered to LNCaP tumor xenografts"，Journal of Nuclear Medicine, [online]，2018年，Vol. 59, (supplement 1)，7，[令和6年8月2日検索], インターネット，<URL: https://jnm.snmjournals.org/content/59/supplement_1/7>

Also Published As

Publication number Publication date
CN114401947A (zh) 2022-04-26
US11504441B2 (en) 2022-11-22
JP2025069156A (ja) 2025-04-30
US20210338851A1 (en) 2021-11-04
KR20220024595A (ko) 2022-03-03
CA3144094A1 (en) 2020-12-24
BR112021025810A2 (pt) 2022-05-10
IL288960A (en) 2022-02-01
CN119431260A (zh) 2025-02-14
WO2020252598A1 (en) 2020-12-24
EP3986872A4 (en) 2024-02-21
IL288960B1 (en) 2026-03-01
AU2020296488A1 (en) 2022-01-20
US20230114807A1 (en) 2023-04-13
CN114401947B (zh) 2024-11-29
JP2022537773A (ja) 2022-08-29
EP3986872A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
JP7618599B2 (ja) 前立腺特異的膜抗原を標的とする放射性標識化合物
JP7659268B2 (ja) デュアルモード１８ｆ標識セラノスティック化合物及びその使用
AU2020257786B2 (en) Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
JP7541532B2 (ja) 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
US20250186627A1 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
US20240018110A1 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2024016071A1 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
JP2025513489A (ja) Ｃｘｃｒ４標的化合物、およびその作製方法、およびその使用方法
US20250195702A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
BR122025011654A2 (pt) Compostos radiomarcados de direcionamento de antígeno de membrana específico da próstata, seus usos, composição e método de imageamento
WO2025054727A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
WO2025111712A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250108

R150 Certificate of patent or registration of utility model

Ref document number: 7618599

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150